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Familial amyloidosis, Finnish type is caused by a single base mutation in gelsolin, an actin filament severing and capping protein that is present 
in most tissues and in blood plasma. The mutation replaces aspartic acid with asparagine at residue 187 of the plasma sequence. This renders the 
gelsolin susceptible to proteolysis as a consequence of which amyloid protein is formed. Here it is shown that the mutant protein in plasma from 
a patient homozygous for this mutation lacks both actin severing and nucleating activities. Evidence is presented that the cleaved mutant gelsolin 
has dissociated under non-denaturing conditions and that the resultant 65,000 and 55,000 M, C-terminal fragments aggregate. 
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1. INTRODUCTION 
Familial amyloidosis, Finnish type (FAF) is an au- 
tosomal dominant form of systemic amyloidosis that is 
characterized by cornea1 lattice dystrophy, cranial neu- 
ropathy, skin changes as well as renal complications, 
which are very severe in homozygotes [l]. The disease 
arises as a result of a single nucleotide substitution G654 
to A6% in the genomic DNA sequence of gelsolin [2,3], 
which replaces Asp at residue 187 with Asn. Gelsolin is 
a calcium-dependent actin filament severing and cap- 
ping protein that is present in a wide variety of tissues 
and also in blood plasma [4]. Based on the amino acid 
sequence [5], it is composed of six repeating segments 
(Sl-6) [6]. AsP’*~ is located in S2, the F-actin binding 
domain [7]. An aspartic acid residue is conserved at this 
position in all six segments of gelsolin and in equivalent 
segments of other proteins of the gelsolin family, includ- 
ing villin, severin and fragmin [6], suggesting that an 
acidic residue at this position is important for the integ- 
rity of these proteins. The amyloid protein of 8,100 M, 
contains residues Ala173-Met”3 of plasma gelsolin and 
there is a smaller minor component corresponding to 
Ala173-Arg225 [8]. Experiments in vitro have shown that 
a synthetic peptide corresponding to Ala’73-Gly202 con- 
taining Asn at residue 187 has an order of magnitude 
greater tendency to form amyloid fibrils than the same 
peptide containing aspartic acid at this position [9]. 
*Corresponding author. Fax: (44) (223) 213 556. 
Abbreviations: Sl-S6 refers to the six repeating segments of sequence 
in gelsolin and related proteins like villin. 
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The smallest part of gelsolin that retains severing 
activity is Sl-2 [7]. Sl contains the high affinity mono- 
mer binding site [lO,l l] and S2 the filament binding 
domain [7]. The structure of Sl has recently been solved 
at 2.5 A resolution in its complex with G-actin [12]. This 
structure shows that Asp% of Sl (equivalent o Aspie 
of S2) forms a salt bridge with a buried arginine residue, 
Arg45. Because of the high degree of sequence homology 
between these two domains it seems likely that they 
have a similar structural fold. If this is so, Aspls7 would 
be expected to form a salt bridge with Arg’69, the equiv- 
alent residue to Arg4’ in S2. Mutation of the Asp to Asn 
would leave the arginine charge uncompensated and 
this would be expected to produce a local structural 
rearrangement o solvate the charge. A likely conse- 
quence would be increased flexibility of neighbouring 
residues that might make Arg’72, positioned at the start 
of a surface loop, more accessible to proteases. 
Although it is clear that this single mutation is the 
origin of the amyloidosis, it is not clear whether proteol- 
ysis occurs immediately after the gelsolin has been syn- 
thesized or following secretion into the plasma. Nor is 
it known whether the intracellular form of gelsolin is 
cleaved in the same way as the secreted form. Because 
blood plasma contains many proteases, proteolysis of 
the secreted variant might occur more readily. It has 
recently been shown that circulating gelsolin in FAF 
patients (homozygotes) contains a major 65,000 M, spe- 
cies, detected by immunoblotting with antigelsolin anti- 
body, that is not present in normal plasma [13]. There 
is little staining in the region of the gel corresponding 
to intact gelsolin. A minor band is also seen at 55,000 
M,, which is consistent with the second cleavage at 
Met243. Since these fragments were detected only in the 
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presence of SDS, this provides no information about the 
state of undenatured protein in the plasma. 
A further question concerns the actin binding activity 
of the mutant gelsolin. Here we show that the severing 
activity of gelsolin in plasma from homozygous FAF is 
less than 5% of normal values. The severing activity is 
also reduced (by about 50%) in plasma from heterozy- 
gotes. We further show from immunoblots of gels run 
under non-denaturing conditions that the abnormal gel- 
solin migrates in a different position from controls, con- 
sistent with its having fallen apart in the absence of 
denaturing agents. 
2. MATERIALS AND METHODS 
Plasma samples were collected from 10 patients with FAF, 5 unaf- 
fected family members and from other control subjects. The plasma 
was stored frozen at -20°C. Based on oligonucleotide hybridization 
[3], 9 of the patients were heterozygous and one homozygous for the 
Asn’*’ gelsolin mutation. Samples (50 ~1) of plasma were tested blind 
in an actin severing assay as described previously [14] and the rate 
constant for disassembly of 200 nM actin (containing 15% pyrenyl 
actin) was measured. Rate constants were also measured using differ- 
ent volumes of individual samples to determine the concentration 
dependence of the severing rate. The slope of a plot of k,, as a 
function of gelsolin concentration is a measure of the number of ends 
generated by severing action, i.e. the concentration of active gelsolin 
in the plasma [14]. Measurements were also made of the nucleating 
potential of the plasma gelsolin [14]. 
PAGE under non-denaturing conditions was carried out as de- 
scribed by Safer [15] and electroblotted onto nitrocellulose [16]. The 
gelsolin was detected with murine monoclonal anti-gelsolin (Sigma) 
and an amplification system using Vectastain (biotinylated anti mouse 
IgG, avidin and biotinylated peroxidase with diaminobenzidine as 
substrate (Vector Laboratories Ltd. Bretton, Peterborough PE3 8RF, 
UK)). Two dimensional gels were carried out using the Safer system 
in the first dimension and 10% SDS-PAGE in the second [17]. Gels 
were electroblotted as described above and the blots scanned on an 
Apple Color1 Scanner and images compiled using Adobe Photoshop 
2.5 programme. 
Actin was fluorescently labelled at CYS”~ with N-pyrenyl iodoacet- 
amide as described previously [14]. Kinetics measurement were made 
using a Perkin-Elmer LS-50 spectrofluorimeter and exponential reac- 
tions analysed by non-linear least squares analysis with Enzlitter 
(Biosoft, Cambridge). 
3. RESULTS 
The actin severing activity of 21 different samples of 
frozen plasma was measured using 50 ~1 volumes and 
compared with freshly prepared plasma from one of the 
authors. Based on the observed activities, the results 
were classified into 4 groups, two of which showed sev- 
ering activity substantially below that of the fresh 
plasma sample and one with somewhat higher activity 
(Table I). Six of the samples gave a mean value similar 
to that of fresh plasma and there was very good agree- 
ment between 2 different samples of frozen plasma from 
the same individual. The origin of the samples was not 
known until after the analysis was completed. With a 
single exception, all of these 6 samples were from con- 
trols or unaffected family members; the exception was 
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from a heterozygote who was asymptomatic for amy- 
loidosis. The group of samples with somewhat higher 
severing activity were from four different unaffected 
family members. Eight samples showed about 50% of 
the activity of the main group of controls: all were from 
different heterozygotes. The fourth group with activity 
5% that of controls were from the single homozygote, 
one from a plasma sample taken a year later than the 
other two. 
Although determination of /cobs using a single volume 
of plasma from each sample should provide a reliable 
measure of severing activity, a more accurate method is 
to compare kobs values using different concentrations of 
each sample [14]. Fig. 1 shows results for a single mem- 
ber from each of the four groups in Table I. The sever- 
ing activity in plasma from the homozygote is less than 
2% that of the control value, while that from the 
heterozygote is about 50%. Analysis of one of the gel- 
solins in the high activity class showed a severing fre- 
quency that was only 20% above the control values. 
This suggests that Class 2 of Table I does not represent 
a significantly higher activity than the controls, but we 
have no explanation for the higher apparent activity 
observed using the 50 ~1 volumes. 
Nucleation experiments were carried out with indi- 
vidual samples from control and FAF patients. Control 
plasma samples eliminated the lag phase in actin polym- 
erization in a manner similar to pure gelsolin (Fig. 2). 
Comparing the exponential rate constant {= k’N, 
where k’ is the association rate constant at the pointed 
end and [Nj the gelsolin concentration [14]} with a gel- 
solin standard suggested a concentration of gelsolin in 
the plasma of 1.8 ,uM. Plasma from the heterozygote 
also eliminated the lag phase of polymerization and 
gave a nucleating activity at 3 different concentrations 
that was 53% of the control value. Plasma from the 
homozygote, used at 5 times the concentration of con- 
trol and heterozygote samples, did not reduce the lag 
phase of actin polymerization. There was a substantial 
reduction in the end point of polymerization with this 
sample, consistent with a reduced concentration of 
polymerizable actin (see below). This can be seen by 
comparing arrow A with B. The other plasma samples 
also reduced the extent of polymerization as determined 
Table I 
Severing activity in 50 ~1 of blood plasma 
Class Number of 
samples 
kobs x 1000/s/50 ~1 FAF 
I 6 10.1 t 1.31 No 
II 4 17.7 f 2.03 No 
III 8 5.55 f 1.11 Heterozygote 
IV 3 0.551 f 0.1 I Homozygote 
The activity obtained for 50 ~1 of fresh plasma was 10.4 x lO-31s. 
20 nM gelsolin gave an activity of 3.77 x IO-‘/s, suggesting that the 
concentration of gelsolin in this plasma sample is 1.7 PM. 
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Fig, 1. Severing activity of plasma samples from Class I, controls or 
unaffected family members (solid squares, 0.243); Class 2, unaffected 
family members (open squares, 0.299); Class 3, heterozygotes (open 
circles, 0.124) and Class 4, homozygote (open triangles, 0.0046). The 
severing activities (given in parentheses) are the slopes of the lines 
expressed as s? ml-‘. 
from the final fluorescence value after several hours, but 
the effect was less marked because samples were 
smaller. This reduction is probably due to the presence 
of vitamin D binding protein, which sequesters actin 
monomers [ 181. 
The reduced severing and nucleating activities of the 
gelsolin might be caused by a lower concentration of 
gelsolin in the plasma or by defective actin binding ac- 
tivity of the mutant protein. Plasma samples were analy- 
sed by gel electrophoresis under non-dissociating condi- 
tions and the gelsolin was detected by immunoblotting. 
Fig. 3 shows that control gelsolin migrated as a group 
of closely spaced bands, the mobility of which were 
identical to those obtained using bacterially expressed 
gelsolin (not shown). Immunostaining of plasma sam- 
ples from the homozygote showed a series of bands of 
much lower mobility, although there was also very weak 
staining in the same position as control samples, Sam- 
ples from heterozygotes howed both sets of bands, at 
roughly equal intensity (not shown). The difference in 
mobility suggests that the mutant gelsolin in non-dena- 
tured form has a significantly different size or net charge 
from the control. Two-dimensional gel electrophoresis 
confirmed that the lower mobility bands of the homozy- 
gote corresponded to the 65,000 and 55,000 1M, compo- 
nents of cleaved mutant gelsolin. The lower part of Fig. 
3 shows a composite 2-dimensional gel containing both 
forms of gelsolin. 
4. DISCUSSION 
Our results show that mutant gelsolin in the plasma 
of a patient homozygous for the Asn’87 mutation is 
almost completely inactive in its severing and nucleating 
properties. Plasma from patients heterozygous for the 
mutation showed significantly lower activities, about 
50% of control values. We were unable to show whether 
the actin monomer binding activity of the mutant gel- 
solin is also reduced, because plasma contains high con- 
centrations of vitamin D binding protein, which also 
binds monomeric actin [18]. This can be seen in Fig. 2 
which shows about 50% reduction in the concentration 
of polymerizable actin in the presence of 50 ~1 of plasma 
from the homozygote, even though the mutant gelsolin 
was inactive both in its severing and nucleating activi- 
ties. 
Loss of actin severing and nucleating activity of the 
mutant gelsolin might reflect a lower concentration of 
mutant gelsolin in the plasma. We do not believe that 
this is the case. The staining intensities of the mutant 
and control gelsolin in the plasma samples on im- 
munoblots (Fig. 3) suggest hat the concentrations are 
not significantly different, assuming that the extent of 
transfer to nitrocellulose is similar for all samples. These 
immunoblots were run under conditions in which gel- 
solin was the limiting component; assuming the plasma 
concentration of gelsolin is 1.7-1.8 PM (from nuclea- 
tion assays and Table I; this is consistent with previous 
estimates using the DNase I in~bition assay [17]), each 
slot on the gel contains 3.5 pmol gelsolin and the anti- 
body is added at 66 nM. 
Comparison of mutant and control gelsolins by elec- 
trophoresis under non-denaturing conditions shows 
that they have very different mobilities (Fig. 3). The 
presence of multiple gelsolin bands in electrophoresis 
under native conditions is not unexpected, because gel- 
solin is resolved into 3 components by isoelectric fo- 
cussing in urea [19-211. The markedly different mobility 
of the mutant gelsolin at pH 8.6 cannot be explained by 
the loss of a single negative charge in a protein with an 
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Fig. 2. Nucleating activity of plasma samples in the polymerization of 
6 NM actin, containing 15% pyrenyl-actin. Actin polymerized in the 
absence of gelsolin or plasma (+ with end point marked by arrow A); 
actin polymerized in the presence of 60 nM gelsolin (no symbols, 
kQb = 7.29 x 1O-3/s); 10 ~1 control plasma (W kot, = 5.49 x IO-‘/s); 
lO@ plasma from heterozygote (0 koba = 3.38 x IO-%); 50 $1 plasma 
from homozygote (A kob = 1.01 x lO?s, with end point marked by 
arrow B). Fluorescence in arbitrary units. 
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A 
B 
Fig. 3. The upper part shows native gel electrophoresis of plasma 
samples containing control (A) and mutant (B) forms of gelsolin, 
stained after transfer to nitrocellulose with anti-gelsolin antibodies. 
The proteins have migrated from right to left towards the anode. The 
lower part is a composite two dimensional gel obtained by superpos- 
ition of gels of control and mutant proteins. Bands labelled A are from 
the control gel A above and the minor upper band is material that has 
not penetrated the gel in the second dimension. The four lower bands 
are from the mutant gelsolin in 3. At the right is a molecular weight 
calibration showing the positions in the SDS-PAGE dimension of 
gelsolin and two of its fragmentation products. 
acidic and 99 basic residues. The mobility difference 
most likely reflects the electrophoretic behaviour of the 
proteolytically cleaved mutant gelsolin. The second di- 
mension in SDS confirms the presence of the expected 
components of 65,000 and 55,000 M, (see composite gel 
in Fig. 3). The antibody used to detect the gelsolin re- 
cognises only epitopes in the C-terminal half of the 
protein 1231. It therefore stains intact gelsolin and the 
65,000 and 55,000 M, bands of the mutant protein, but 
not any of the smaller fragments from the N-terminal 
end of the protein. 
The lower mobility of the mutant protein on non- 
denaturing els is not consistent with expectation, based 
on both the smaller sizes and 35% higher net negative 
charge calculated for the 65,000 and 55,000 A4, compo- 
nents. One explanation is that dissociation of the N- 
terminal fragments from the cleaved protein promotes 
aggregation. This conclusion is supported from experi- 
ments on N-terminal t~ncation of bacterially expressed 
S 1, which showed progressively increased aggregation 
as N-terminal residues were removed [24]. 
The non-denaturing gel of mutant gelsolin also 
showed weak bands in the position corresponding to 
control samples (Fig. 3B) However, the second dimen- 
sion in SDS revealed only trace amounts of 90,000 M, 
protein (not shown). Instead there were two bands of 
about 45,000 M,, suggesting that limited further frag- 
mentation has occurred, possibly during preparation of 
the samples for gel electrophoresis. Storage at 4°C over- 
night or longer of samples containing the glycerol buffer 
for the native gels showed greatly increased fragmenta- 
tion of this kind. 
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Loss of both severing and nucleating activities by the 
mutant gelsolin can be explained by dissociation of the 
N-terminal fragment following proteolysis at Arg’72. 
We have previously shown that a truncated form of 
gelsolin (S2-6), lacking Sl, has no severing activity [ 141. 
By contrast, nucleation by gelsolin does not require S 1, 
since S2-6 has nucleating activity equal to that of intact 
gelsolin. Since 51-3 does not nucleate, the two actin- 
binding domains required for this activity are those in 
S2 and S4-6 [7,14]. Since the bulk of the mutant gelsolin 
migrates with an M, of 65,000 [I 31, loss of nucleating 
activity by the mutant suggests that removal of only the 
first 23 N-terminal residues from S2 is sufficient to de- 
stroy nucleating potential. This is consistent with the 
localization of an F-actin binding site to a 16 residue 
peptide of villin, located within the first 23 residues of 
the corresponding S2 segment of that protein [25]. 
The demonstration that plasma gelsolin is inactive in 
a patient homozygous for FAF and has reduced sever- 
ing activity in heterozygotes may not present a serious 
problem for clearing any F-a&in that is released into the 
bloodstream as a result of tissue damage because other 
actin binding proteins are present. In addition to gel- 
solin, plasma contains high concentrations of vitamin- 
D binding protein [18], which sequesters monomeric 
actin; thus F-actin would be expected to be depolymer- 
ized, albeit more slowly [26]. Loss of activity by cyto- 
plasmic gelsolin is likely to be much more serious if 
gelsolin plays an essential role in cell locomotion and 
motility [27]. However, fragmentation of the mutant 
secreted protein in plasma does not mean that the cyto- 
plasmic variant is similarly fragmented, even though the 
two isoforms arise from the same single gene 1281. 
Plasma is rich in proteases and the secreted variant may 
therefore be much more susceptible to breakdown than 
the cytoplasmic form. More experiments will be needed 
to analyse the properties of mutant cytoplasmic gelsolin 
and to explore the cause of proteolysis in plasma. Be- 
cause insufficient amounts of the mutant are available 
from natural sources, this can only be done by express- 
ing it in bacteria. 
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